Molecular Partners AG (SWX:MOLN)
Switzerland · Delayed Price · Currency is CHF 3.230
+0.020 (0.62%)
Jul 10, 2026, 5:30 PM CET
Molecular Partners AG Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
134
Market Cap
121.16M
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 4.97M | -2.07M | -29.38% |
| Dec 31, 2023 | 7.04M | -182.56M | -96.29% |
| Dec 31, 2022 | 189.60M | 179.85M | 1,843.82% |
| Dec 31, 2021 | 9.75M | 410.00K | 4.39% |
| Dec 31, 2020 | 9.34M | -11.04M | -54.16% |
| Dec 31, 2019 | 20.38M | 10.03M | 96.84% |
| Dec 31, 2018 | 10.36M | -9.66M | -48.27% |
| Dec 31, 2017 | 20.02M | -3.02M | -13.13% |
| Dec 31, 2016 | 23.04M | -6.08M | -20.88% |
| Dec 31, 2015 | 29.12M | 2.49M | 9.37% |
| Dec 31, 2014 | 26.63M | -5.79M | -17.87% |
| Dec 31, 2013 | 32.42M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bachem Holding AG | 695.07M |
| Basilea Pharmaceutica AG | 232.38M |
| Idorsia | 219.10M |
| Santhera Pharmaceuticals Holding AG | 77.19M |
| Newron Pharmaceuticals | 17.81M |
| BioVersys AG | 3.18M |
| MindMaze Therapeutics Holding | 642.00K |
| Xlife Sciences AG | 275.31K |
Molecular Partners AG News
- 6 days ago - Molecular Partners To Advance MP0726 For First Human Imaging In H2,2026; Provides MP0712 Update - Nasdaq
- 7 days ago - Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics - GlobeNewsWire
- 10 days ago - Molecular Partners, Orano Med doses first patient in MP0712 study - TheFly
- 11 days ago - Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712 - GlobeNewsWire
- 6 weeks ago - Molecular Partners to hold trial-in-progress presentations on Phase 1/2a study - TheFly
- 6 weeks ago - Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1 - GlobeNewsWire
- 6 weeks ago - Molecular Partners AG Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Transcripts
- 6 weeks ago - Molecular Partners to Present at TD Cowen's 7th Annual Oncology Innovation Summit - GlobeNewsWire